CClinicalTrials.gg
CompletedNCT02361970Updated May 23, 2017

Study on the Role of Gamma Delta T Cells in Sepsis Immunosuppression and Its Molecular Mechanism

An observational study in Sepsis, sponsored by West China Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-23.

Sponsored by West China Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
84
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the status and function of gamma delta T cells in peripheral blood of sepsis patients.

Read the detailed description

Sepsis therapy is a prominent problem of the modern critical care medicine,and improving the level of sepsis treatment by immune intervention measures is a hot research topic with close attention.Gamma delta T cells is considered as one new T lymphocyte subset in recent years,which playing an important role in resistance to infection,anti-tumor and immune regulating function in the body.First,we played attention to the status and function of gamma delta T cells in peripheral blood of sepsis patients including differentiation marker,subtype and production of related cytokine,and then the molecular mechanism of insufficient gamma delta T cells.At the same time the responsibility of gamma delta T cells of sepsis patients to certain bacteria and viral antigen and the regulation of gamma delta T cells on other natural immune cells including NK cells and mononuclear cells were studied to identify the status and role gamma delta T cells in sepsis immunosuppression by culture in vitro.Further we studied the effect of specific stimulants on proliferation and activation of gamma delta T cells in patients with sepsis and also anti-infection acquired by gamma delta T cells,expecting as an entry point to explore new treatment strategy to sepsis.

02

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • sepsis
  • gamma delta T cells
  • immunosuppression
03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.

This study's enrollment of 84 is below the median of 160 across 931 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients admitted in ICUs of West China Hospital

Inclusion criteria

  • clinical symptoms of severe sepsis and septic shock
  • age over 18 years

Exclusion criteria

Exclusion Criteria:

  • preexisting autoimmune disease
  • patients received immuno-suppressive treatment in the previous 6 months
  • patients with chronic infection,e.g.tuberculosis,hepatitis or HIV infection,etc.
  • pregnancy
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
84 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • severe sepsis and septic shock

    patients were diagnosed severe sepsis or septic shock

  • patient control

    Patients after elective surgeries presented with SIRS but without sepsis

  • volunteer

    Health persons

06

What researchers measure

Primary outcomes

  1. The percentage of activated gamma delta T cells

    Time frame: within 24h after recruitment

Secondary outcomes

  1. The percentage of apoptotic gamma delta T cells

    Time frame: within 24h after recruitment

07

Study locations

1 site
  • West China Hospital,Sichuan University
    Chengdu, Sichuan 610041, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02361970
Lead sponsor
West China Hospital
Responsible party
Kang Yan (Director of Intensive Care Unit, West China Hospital) — Principal investigator
First posted
Feb 12, 2015
Start date
May 2014
Primary completion
May 2015
Completion
May 2015
Last update
May 23, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion